Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people
each year and is the second most common hematologic malignancy. It is part of a spectrum …

Bisphosphonates are effective in the prevention and treatment of bone disease in multiple
myeloma (MM). Osteonecrosis of the jaw is increasingly recognized as a serious complication …

… PAI1, von Willebrand factor, 34 fibronectin, 69 homocysteine 70 and thrombomodulin, 71
and reduced levels of anticoagulant proteins, including antithrombin III, protein C and protein S …

Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction
of novel therapies and the increased use of high-dose therapy have translated into better …

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the
introduction of new drugs, but it is not clear whether the improvements have been sustained. We …

Purpose Cardiac involvement predicts poor prognosis in light chain (AL) amyloidosis, and
the current prognostic classification is based on cardiac biomarkers troponin-T (cTnT) and N-…

We report the results of a phase 2 trial using lenalidomide plus dexamethasone (Rev/Dex)
as initial therapy for myeloma. Thirtyfour patients were enrolled. Lenalidomide was given …

Purpose: Multiple myeloma is a malignancy of plasma cells and is characterized by increased
marrow angiogenesis. Thalidomide, an agent with antiangiogenic properties, is effective …

Multiple myeloma remains an incurable neoplasm of plasma cells that affects more than
20,000 people annually in the United States. There has been a veritable revolution in this …

While initial therapies have become highly effective with introduction of lenalidomide and
bortezomib and patients may opt for delayed stem cell transplantation, it is important to collect …